News | January 27, 2015

Ortho-Clinical Diagnostics Introduces Test to Assess Risk for Acute Kidney Injury

Early knowledge of AKI risk may prompt closer patient monitoring and help prevent permanent kidney damage or death

Nephrocheck Test System, Blood testing, contrast media

Image courtesy of Astute Medical

January 27, 2015 — Ortho-Clinical Diagnostics Inc. announced the nationwide availability to hospitals of the Nephrocheck Test System designed to help healthcare providers identify patients at risk of developing moderate or severe acute kidney injury (AKI) within 12 hours of patient assessment.

In comparing patients with AKI to patients without AKI, hospital and the intensive care unit lengths of stay double, as do costs of care and readmission rates.  Death rates at one year are higher among patients with AKI alone, compared to those patients with heart attack alone.

AKI usually lacks signs and symptoms and can potentially result in irreversible kidney damage if recognition is delayed. In clinical studies, the Nephrocheck Test identified the majority of patients that developed moderate to severe AKI within 12 hours of assessment.

The Nephrocheck Test result, called the AKIRisk Score, has the ability to distinguish patients with AKI from those without AKI. Based on results from clinical studies, patients with a positive AKIRisk Score (greater than the cutoff of 0.3) have a one in four to a one in three chance of developing moderate or severe AKI within 12 hours of assessment.

To calculate the AKIRisk Score, the Nephrocheck Test System measures the concentrations of two urinary biomarkers using the Astute140 Meter. The two novel biomarkers -- tissue inhibitor of metalloproteinase 2 and insulin-like growth factor binding protein 7, are thought to be involved in G1 cell cycle arrest in the earliest phases of injury.

In July 2014, Ortho-Clinical Diagnostics entered into collaboration with Astute Medical Inc., the developer of the Nephrocheck Test System, to become the exclusive sales agent for Astute Medical’s Nephrocheck Test and the Astute140 Meter in the United States and in certain countries of the European Union.

For more information: www.orthoclinical.com/en-us/Pages/Home.aspx, www.astutemedical.com

 

 

Related Content

ISMRM Issues Guidelines for MRI Gadolinium Contrast Agents
News | Contrast Media | August 15, 2017
The International Society for Magnetic Resonance in Medicine (ISMRM) has provided new guidance in the use of contrast...
Contrast Media from Bayer, trends in contrast media and developments in contrast media
Feature | Contrast Media | July 28, 2017 | By Dave Fornell
Here are several updates in medical imaging ...
Guerbet Announces Plans to Streamline Contrast Media Portfolio, gadolinium MRI contrast
News | Contrast Media | July 18, 2017
July 18, 2017 — Guerbet recently announced that it will phase out sales throughout the world of two products: Hexabri
ACR Offers Revised Contrast Media in Imaging Manual
News | Contrast Media | July 17, 2017
The American College of Radiology (ACR) recently revised its authoritative guide for the safe and effective use of...
FDA says gadolinium retention in the brain is not a safety issue
Feature | Magnetic Resonance Imaging (MRI) | May 25, 2017
A U.S. Food and Drug Administration (FDA) review of the safety ramifications of gadolinium-based contrast agents for...
Targeted MRI Could Pinpoint Aggressive Prostate Cancers Before They Spread

The ZD2-Gd probe, represented by the orange ball and green arrow, binds to the EDB-FN in the prostate cancer cells with high metastatic potential. This results in a strong MRI signal (upper right). Prostate cancer cells with low metastatic potential have no EDB-FN and so there is no MRI signal (lower right). Credit: Han, et al., Bioconjug Chem-Apr-2017

News | Prostate Cancer | May 24, 2017
A research team funded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) has engineered a...
Scientists Develop Novel Chemical Dye to Improve MRI Liver Cancer Imaging
News | Magnetic Resonance Imaging (MRI) | May 03, 2017
May 3, 2017 — Scientists from the National University of Singapore (NUS) have developed a novel nanodiamond-based ...
Sponsored Content | Case Study | Contrast Media Injectors | April 13, 2017
The volume of computed tomography (CT) imaging exams continues to grow in the United States,[2] adding pressure to...
PRAC, European Medicines Agency, gadolinium-based contrast agents, safety recommendations, brain MRI
News | Contrast Media | March 13, 2017
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency recently released new...
Overlay Init